Cutting-edge deep learning solutions that work with radiologists to improve breast cancer detection to be launched in Oman

Kheiron Medical Technologies partners with Waleed Pharmacy & Stores to bring AI breast screening solution Mia® to Oman healthcare community

  
  • Mia is the first and only AI-enabled independent reader for breast cancer screening to be commercially available in Oman

Muscat: – Mia®, a deep learning artificial intelligence (AI) solution that works with radiologists to improve breast cancer detection, avoid unnecessary biopsies and ultimately improve the patient experience for all women is being launched in Oman.

UK-based Kheiron Medical Technologies has signed an agreement with Waleed Pharmacy & Stores LLC, an Omar Zawawi Establishment (OMZEST) group company focused on bringing healthcare, hospital and pharmaceutical solutions to Oman, to bring its Mia solution to the Oman market. With patented AI technology developed on more than three million breast images, Mia (Mammography Intelligent Assessment) is designed to support breast radiologists in making the critical decision to recall women for further testing based on their mammography screening.

Mia is the first solution of its kind to receive the CE (European regulatory clearance) mark for use as an AI-enabled independent reader for the detection of breast cancer. Through rigorous clinical studies and testing, Mia has learnt to read mammograms to the same level of detail as a consulting radiologist.

In double-reading mammography workflows where scans are reviewed by two radiologists, Mia can be deployed independently alongside a single human reader. This delivers the quality improvements needed to ensure the sustainability of breast screening services and frees up clinicians to spend more time with patients. Mia can also be deployed as a concurrent reader or in double reader triage.

Her Majesty’s Trade Commissioner for the Middle East, Simon Penney, added: “I am delighted that Kheiron Medical Technologies is bringing their breakthrough AI platform for breast screening, Mia, to the Gulf region, and that the UK’s Department for International Trade played a role in making this happen.  Kheiron’s technology brings pioneering artificial intelligence to the frontline, freeing up clinicians’ time and helping to save lives.”

Speaking at a signing ceremony between Kheiron and Waleed Pharmacy, Alex Hamlow, Kheiron’s Chief Commercial Officer, said; “Our mission at Kheiron is to support breast screening professionals in the fight against breast cancer with proven and effective AI-enabled tools. We’re excited that Mia is the first AI independent reader solution available for use within the breast screening community in Oman. Based on its performance in the UK and Europe, Mia represents a major breakthrough in helping radiologists to dramatically improve breast cancer detection and patient outcomes.

“According to the WHO’s International Agency for Research on Cancer, breast cancer was the most prevalent of all cancers detected in Oman in 2020, accounting for 37.7% of all new cancer cases detected in women. I’m excited that Mia can help both radiologists and the women they care for,” Mr Hamlow continued.

“We are proud to partner with Kheiron Medical Technologies,” comments Pawan Mordani, General Manager for Waleed Pharmacy.  “Mia can make a real difference for radiologists and for women, and it will add great value to the ongoing breast-screening initiatives in the Sultanate of Oman.”

Mia’s effectiveness has been proven in one of the most ambitious clinical studies in radiology AI to date and tested across multiple demographics and mammography devices.  It was one of the recipients of the UK Government’s first AI in Health and Care Awards through which Mia is undergoing multiple deployments and clinical studies across 15 sites in the UK as a benchmark for how to integrate new, cutting edge technologies into the NHS safely and effectively. Kheiron and AI Advance are currently working with an Australian breast-screening provider to establish the protocols for a forthcoming clinical trial, details of which will soon be announced.

Mia will be available to the UAE, Qatar and Oman markets pending local requirements.

-Ends-

About Kheiron Medical Technologies

Founded in 2016 by Peter Kecskemethy and Tobias Rijken, Kheiron Medical Technologies is an applied science company focused on supporting cancer diagnostics with machine learning that works with radiologists so that every patient has a better fighting chance. Its initial focus is improving the outcomes for the more than two million women diagnosed globally every year with breast cancer.  Operating in the United Kingdom, United States, and Europe, Kheiron is an international, multi-disciplinary team of senior clinicians, industry experts, engineers and machine learning scientists.

About Waleed Pharmacy & Stores LLC                  

Waleed Pharmacy & Stores LLC is an Omar Zawawi Establishment (OMZEST) group company focused on bringing healthcare, hospital and pharmaceutical solutions to the Sultanate of Oman. Driven by the vision to help develop the nation’s healthcare infrastructure through superior patient care and satisfaction, the company partners with industry-leading healthcare vendors to provide cost-effective products and timely services for the Oman market.

For more information, please contact:
Gina Mehmert
VP, Global Commercial Marketing
Kheiron Medical Technologies
gina@kheironmed.com 

Send us your press releases to pressrelease.zawya@refinitiv.com

© Press Release 2021

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.


More From Press Releases